Why Oral GLP-1s Have Absorption Challenges Injectables Don't
Key Takeaways
- Oral GLP-1 peptides (semaglutide) have ~1% bioavailability without absorption enhancers — 99% gets destroyed by stomach acid
- The SNAC technology in Wegovy/Rybelsus pills raises local pH and improves absorption, but still requires a strict fasting protocol
- Orforglipron (Foundayo) avoids this entirely — it's a small molecule, not a peptide, so stomach acid doesn't degrade it
- Compounded oral formats use alternative routes (sublingual, buccal) to bypass the stomach, but with less published data
- Injectables have ~90%+ bioavailability — the absorption gap is real and affects dosing
Every injectable GLP-1 patient gets roughly 90% of their dose into their bloodstream. Every oral GLP-1 patient faces a fundamental pharmacological challenge: the human digestive system is designed to destroy exactly the type of molecule that GLP-1 medications are made of. Here's why that matters and how different products address it.
Why Peptides and Stomachs Don't Get Along
Semaglutide and tirzepatide are peptides — chains of amino acids held together by peptide bonds. Your stomach's entire job is breaking peptide bonds. Hydrochloric acid (pH ~1.5–3.5) denatures the peptide's structure, and pepsin enzymes cleave it into fragments too small to activate GLP-1 receptors.
The result: oral bioavailability of unprotected semaglutide is approximately 1%. To make a pill that delivers the equivalent of a 2.4 mg injection, you'd theoretically need hundreds of milligrams of active ingredient — which is why oral Wegovy uses 25 mg of semaglutide with SNAC technology to boost absorption.
How SNAC Technology Works
SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) is co-formulated with semaglutide in each Wegovy pill and Rybelsus tablet. When the tablet dissolves in the stomach:
- SNAC creates a local pH buffer around the tablet, temporarily raising pH to protect the peptide
- SNAC enhances absorption through the gastric epithelium (stomach lining) via a transcellular pathway
- The process is concentration-dependent — it works best when the stomach is empty and the tablet sits directly against the stomach wall
This is why the fasting protocol matters. Food in the stomach dilutes the SNAC concentration, physically separates the tablet from the stomach lining, and reduces absorption by as much as 40–50%.
The Small-Molecule Advantage
Orforglipron (Foundayo) sidesteps the entire problem. It's not a peptide — it's a small organic molecule that activates the GLP-1 receptor through a different binding site. Small molecules are chemically stable in acid, resistant to enzymatic degradation, and absorb well through the intestinal lining without any enhancement technology.
The practical result: Foundayo has significantly higher oral bioavailability than oral semaglutide, no fasting requirement, and more predictable absorption. This is fundamentally why Eli Lilly invested in a small-molecule GLP-1 program rather than trying to improve peptide oral delivery.
What This Means for Compounded Oral Formats
Compounded oral semaglutide — whether as troches, sublingual drops, or ODT — faces the same peptide degradation challenge as brand-name pills but without SNAC technology. These formats try to solve the problem by absorbing the peptide through the oral mucosa (mouth lining) rather than the stomach.
The trade-off: mucosal absorption avoids stomach acid, but the oral mucosa has a smaller surface area and tighter cellular junctions than the stomach or intestines. How much semaglutide actually reaches the bloodstream via these routes is not established with published Phase 3 data.
MadeMed
Oral SemaglutideCompounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
Telos Rx
Oral TirzepatideCompounded oral tirzepatide via Telos Rx. First-month pricing starts at $40; ongoing pricing varies by plan length ($160–249/mo).
The absorption challenge is real and explains why oral GLP-1 doses are so much higher than injectable doses (25 mg oral vs. 2.4 mg injection for semaglutide). SNAC technology and small-molecule chemistry are two validated solutions. Compounded oral formats use a third approach (mucosal absorption) that has less published evidence but fills a genuine cost-access gap. Understanding these differences helps you have a more informed conversation with your provider about which format makes sense for you.
Bioavailability estimates are drawn from published pharmacological literature. Consult your healthcare provider about medication format decisions.